Resveratrol as an Antiviral Against Polyomavirus

Berardi, Valerio; Ricci, Francesca; Castelli, Mauro; Galati, Gaspare; Risuleo, Gianfranco

doi:10.1201/b12222-7

Cited by 7 publications

(10 citation statements)

References 62 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liposome encapsulated antibiotics demonstrated a significant increase in antimicrobial activity towards P. aeruginosa bacteria in the presence of DNA, F-actin, lipopolysaccharides and lipoteichoic acid. [44] It is worth noting that co-encapsulation of other antimicrobial substances together with an antibiotic into liposomes could improve the antimicrobial efficacy. Omri and coworkers showed that the co-encapsulation of gallium or bismuth-ethanedithiol with gentamycin or tobramycin in DPPC:Chol or DSPC:Chol, respectively, can increase the vulnerability of the bacterial cells and interfere with the expression of virulence factors, alginate, quorum sensing molecules and biofilm formation compared to the free antibiotic or the free antibiotic and the free metal combined.…”

Section: Protection Of the Antimicrobial Agentmentioning

confidence: 99%

“…This can be attributed to the increase in viscoelasticity which limits the diffusion of the liposomes or a stabilization of the liposomes by the mucus which reduces the release of the antibiotic from the liposomes. [44] Alternatively, the liposomes might bind to alginate, preventing the nanocarrier to bind to the bacteria themselves or destabilizing the liposomes leading to premature release and subsequent inactivation of the antibiotic. [68] Although the addition of DNase and alginate lyase improved the activity of the free and liposomal antibiotics, no superiority of the liposomal formulation was observed.…”

Section: Absence Of Increased Anti-biofilm Effectmentioning

confidence: 99%

“…This optimized protocol was used to prepare the liposomes in several studies discussed in this review. [36,37,44,68] …”

Section: Encapsulation Efficiencymentioning

confidence: 99%

See 2 more Smart Citations

Lipid and polymer nanoparticles for drug delivery to bacterial biofilms

Forier

Raemdonck

Smedt

et al. 2014

Journal of Controlled Release

360

320

View full text Add to dashboard Cite

Biofilms are matrix-enclosed communities of bacteria that show increased antibiotic resistance and the capability to evade the immune system. They can cause recalcitrant infections which cannot be cured with classical antibiotic therapy. Drug delivery by lipid or polymer nanoparticles is considered a promising strategy for overcoming biofilm resistance. These particles are able to improve the delivery of antibiotics to the bacterial cells, thereby increasing the efficacy of the treatment. In this review we give an overview of the types of polymer and lipid nanoparticles that have been developed for this purpose. The antimicrobial activity of nanoparticle encapsulated antibiotics compared to the activity of the free antibiotic is discussed in detail. In addition, targeting and triggered drug release strategies to further improve the antimicrobial activity are reviewed. Finally, ample attention is given to advanced microscopy methods that shed light on the behavior of nanoparticles inside biofilms, allowing further optimization of the nanoformulations. Lipid and polymer nanoparticles were found to increase the antimicrobial efficacy in many cases. Strategies such as the use of fusogenic liposomes, targeting of the nanoparticles and triggered release of the antimicrobial agent ensured the delivery of the antimicrobial agent in close proximity of the bacterial cells, maximizing the exposure of the biofilm to the antimicrobial agent. The majority of the discussed papers still present data on the in vitro anti-biofilm activity of nanoformulations, indicating that there is an urgent need for more in vivo studies in this field.

show abstract

Section: Protection Of the Antimicrobial Agentmentioning

confidence: 99%

Section: Absence Of Increased Anti-biofilm Effectmentioning

confidence: 99%

See 1 more Smart Citation

Lipid and polymer nanoparticles for drug delivery to bacterial biofilms

Forier

Raemdonck

Smedt

et al. 2014

Journal of Controlled Release

360

320

View full text Add to dashboard Cite

show abstract

“…Encapsulation of these antibiotics in liposomes reduces formation of the electrostatic complex 100-fold, giving a 4-fold improved inhibition of P. aeruginosa colonies, suggesting a potential application in eradication of chronic lung infections associated with CF [184,187].…”

Section: Protective Vesicles Preventing Antimicrobial Degradationmentioning

confidence: 99%

“…CF sputum being rich in polyanionic components, namely mucin, DNA, F-actin, lipopolysaccharides and lipoteichoic acid has been shown to reduce the antimicrobial properties of the cationic antibiotics polymyxin and tobramycin, due to formation of an electrostatic-attraction complex, hampering complete eradication of the bacteria [99,187,188]. Encapsulation of these antibiotics in liposomes reduces formation of the electrostatic complex 100-fold, giving a 4-fold improved inhibition of P. aeruginosa colonies, suggesting a potential application in eradication of chronic lung infections associated with CF [184,187].…”

Section: Protective Vesicles Preventing Antimicrobial Degradationmentioning

confidence: 99%

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Merchant

Buckton²,

Taylor³

et al. 2016

CPD

View full text Add to dashboard Cite

Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilmassociated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance.

show abstract

Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study

et al. 2019

View full text Add to dashboard Cite

Cystic fibrosis (CF) patients are faced with chronic bacterial infections displaying persistent resistance if not eradicated during the first stage of the disease. Nanoantibiotics for pulmonary administration, such as liposomal ciprofloxacin or amikacin, have progressed through clinics thanks to their sustained release, prolonged lung residence time and low systemic absorption. In this work, we sought a nanoformulation of levofloxacin for the treatment of Pseudomonas aeruginosa. We prepared and compared PLA-g-PEG nanoparticles, as well as anionic and cationic liposomes for their size, charge and encapsulation efficiency. Cationic liposomes were unable to encapsulate any drug and were subsequently considered as a control formulation. Regarding the efficiency of the nanocarrier, anionic liposomes exhibited a prolonged release over 72 h and preserved the antibacterial activity of levofloxacin against 5 strains of Pseudomonas aeruginosa, whereas polymeric nanoparticles quickly released their entire payload and increased the minimal inhibitory concentration (MIC) of levofloxacin. Thus, only anionic liposomes were considered for further preclinical development. Anionic liposomes exhibited a suitable colloidal stability by Turbiscan analysis and crossed a layer of artificial mucus in under one hour in a Transwell setup. Despite their negative surface charge, liposomes still interacted with P. aeruginosa membrane in a dose-reponse manner, as demonstrated by flow cytometry. Viability assays confirmed that anionic liposomes, loaded or not, exhibited a good safety profile on A549 epithelial cells even at high concentrations. Finally, nebulization of anionic liposomes containing levofloxacin did not impact their colloidal stability and the droplet size distribution was suitable for deep lung deposition, where P. aeruginosa infection lies. Therefore, levofloxacin-loaded anionic liposomes exhibited suitable properties for the pulmonary treatment of P. aeruginosa in CF. This step-by-step study confirms the promising role of liposomes for lung administration of antibiotics, as recently seen in clinics, and fosters their development for several types of antibiotics.

show abstract

Resveratrol as an Antiviral Against Polyomavirus

Cited by 7 publications

References 62 publications

Lipid and polymer nanoparticles for drug delivery to bacterial biofilms

Lipid and polymer nanoparticles for drug delivery to bacterial biofilms

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study

Contact Info

Product

Resources

About